NR3C1 and COVID-19: An independent analysis of CMap classes confirmed glucocorticoid receptor agonists and MEK inhibitors as negatively correlating to the COVIDCS as well as other drugs in clinical trials for the treatment of the COVID-19 CS like JAK inhibitors15,18 (Fig. 2E and Table S7).